Mankind Pharma Limited
MANKIND · ISIN: INE634S01028
Mankind Pharma Limited is a mid cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE634S01028.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
Constituent of NIFTY 500 TRI (0.15%), NIFTY LMC 250 TRI (0.35%), NIFTY MC 150 TRI (0.71%)
CHART
Mankind Pharma Limited - growth of ₹100
Growth of ₹100 invested on 2026-05-08, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-1.38%
3M
-0.01%
6M
+9.91%
1Y
+1.52%
3Y CAGR
+12.34%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Mankind Pharma Limited - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-09-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-09-30.
F&O Sentiment
Nearest expiry: 2026-11-23 · As of 2026-10-28.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-10-26 | SHORT_SELL | 10 |
| 2026-10-05 | SHORT_SELL | 8,750 |
| 2026-08-18 | SHORT_SELL | 100 |
| 2026-08-11 | SHORT_SELL | 1 |
| 2026-08-07 | SHORT_SELL | 12 |
| 2026-07-31 | SHORT_SELL | 500 |
Frequently asked questions
What is Mankind Pharma Limited's 1-year and 3-year return?
Mankind Pharma Limited's 1-year price return is +1.52%. Its 3-year CAGR (annualized return) is +12.34%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Mankind Pharma Limited's latest financial performance?
Mankind Pharma Limited's trailing-twelve-month (TTM) revenue as of 2026-09-30 is ₹15,379 Cr, with a TTM profit after tax of ₹2,264 Cr and an EBITDA margin of 21.89%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹54.33.
What is Mankind Pharma Limited's quality score?
Mankind Pharma Limited has a Punji quality score of 69.2 out of 100 as of 2026-09-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Mankind Pharma Limited's technical indicators show?
As of 2026-10-29, Mankind Pharma Limited's RSI (14-day) is 56.91 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Mankind Pharma Limited?
As of 2026-09-30, Mankind Pharma Limited's shareholding is split across Promoter (72.62%), Public (27.38%). Promoter holding of 72.62% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Is Mankind Pharma Limited part of any major market index?
Yes - Mankind Pharma Limited is a constituent of NIFTY 500 TRI (0.15% weight) and NIFTY LMC 250 TRI (0.35% weight) and NIFTY MC 150 TRI (0.71% weight). Index membership means the stock is automatically bought by every index fund and ETF tracking that benchmark, in proportion to its weight, which brings a baseline level of passive-fund demand independent of active investor sentiment. A stock's weight in an index is typically determined by its free-float market capitalization relative to the index's other constituents, and is periodically rebalanced as relative market caps shift.
What does the F&O market show for Mankind Pharma Limited?
As of 2026-10-28 (nearest expiry 2026-11-23), Mankind Pharma Limited's put-call ratio by open interest is 1.1518 - above 1, typically read as bearish positioning (more open interest on puts than calls). The max pain strike is ₹2480, the price at which option writers as a group would owe the least to option buyers at expiry - a reference level some traders watch, not a price target. F&O positioning reflects derivatives-market sentiment over a specific expiry window, not a fundamental view on the company.
Has Mankind Pharma Limited seen any recent bulk or block deals?
Yes, as of 2026-10-26 - the most recent recorded deal was a SHORT_SELL on 2026-10-26 for 10 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
Stock data · Not financial advice · Past performance does not indicate future returns